Wave Life Sciences says FDA feedback supports registrational pathway for Wve-006 in AATD
WVE•Wave Life Sciences said FDA feedback supports a registrational pathway for Wve-006, an RNA-editing treatment for AATD. The company plans a two-year registration trial with a one-year interim analysis for accelerated approval and expects to share 600 mg multidose cohort data in Q4 2026.
1. Trial plans and safety
Wave Life Sciences plans a two-year registration trial of Wve-006 with a one-year interim analysis for accelerated approval. The company said the treatment continues to be generally safe and well tolerated, with no liver toxicities, and it remains on track to share 600 mg multidose cohort data in Q4 2026.
